Biology subjects

Adeshina, Y.

Publications and source records attributed to Adeshina, Y..

4 recordsLinked to original sources

bioRxiv2024

PINDER: The protein interaction dataset and evaluation resource

Protein-protein interactions (PPIs) are fundamental to understanding biological processes and play a key role in therapeutic advancements. As deep-learning docking methods for PPIs gain traction, benchmarking protocols and datasets tailored for effective training and evaluation of their generalization capabilities and performance across real-world scenarios become imperative. Aiming to overcome limitations of existing approaches, we introduce PINDER, a comprehensive annotated dataset that uses structural clustering to derive non-redundant interface-based data splits and includes holo (bound), apo (unbound), and computationally predicted structures. PINDER consists of 2,319,564 dimeric PPI systems (and up to 25 million augmented PPIs) and 1,955 high-quality test PPIs with interface data leakage removed. Additionally, PINDER provides a test subset with 180 dimers for comparison to AlphaFold-Multimer without any interface leakage with respect to its training set. Unsurprisingly, the PINDER benchmark reveals that the performance of existing docking models is highly overestimated when evaluated on leaky test sets. Most importantly, by retraining DiffDock-PP on PINDER interface-clustered splits, we show that interface cluster-based sampling of the training split, along with the diverse and less leaky validation split, leads to strong generalization improvements.

bioinformatics↗

bioRxiv2024

PLINDER: The protein-ligand interactions dataset and evaluation resource

Protein-ligand interactions (PLI) are foundational to small molecule drug design. With computational methods striving towards experimental accuracy, there is a critical demand for a well-curated and diverse PLI dataset. Existing datasets are often limited in size and diversity, and commonly used evaluation sets suffer from training information leakage, hindering the realistic assessment of method generalization capabilities. To address these shortcomings, we present PLIN-DER, the largest and most annotated dataset to date, comprising 449,383 PLI systems, each with over 500 annotations, similarity metrics at protein, pocket, interaction and ligand levels, and paired unbound (apo) and predicted structures. We propose an approach to generate training and evaluation splits that minimizes task-specific leakage and maximizes test set quality, and compare the resulting performance of DiffDock when retrained with different kinds of splits.

biochemistry↗

bioRxiv2023

Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicry

RNA-binding proteins (RBPs) are key post-transcriptional regulators of gene expression, and thus underlie many important biological processes. Here, we developed a strategy that entails extracting a "hotspot pharmacophore" from the structure of a protein-RNA complex, to create a template for designing small-molecule inhibitors and for exploring the selectivity of the resulting inhibitors. We demonstrate this approach by designing inhibitors of Musashi proteins MSI1 and MSI2, key regulators of mRNA stability and translation that are upregulated in many cancers. We report this novel series of MSI1/MSI2 inhibitors is specific and active in biochemical, biophysical, and cellular assays. This study extends the paradigm of "hotspots" from protein-protein complexes to protein-RNA complexes, supports the "druggability" of RNA-binding protein surfaces, and represents one of the first rationally-designed inhibitors of non-enzymatic RNA-binding proteins. Owing to its simplicity and generality, we anticipate that this approach may also be used to develop inhibitors of many other RNA-binding proteins; we also consider the prospects of identifying potential off-target interactions by searching for other RBPs that recognize their cognate RNAs using similar interaction geometries. Beyond inhibitors, we also expect that compounds designed using this approach can serve as warheads for new PROTACs that selectively degrade RNA-binding proteins.

biochemistry↗

bioRxiv2020

Machine learning classification can reduce false positives in structure-based virtual screening

With the recent explosion in the size of libraries available for screening, virtual screening is positioned to assume a more prominent role in early drug discoverys search for active chemical matter. Modern virtual screening methods are still, however, plagued with high false positive rates: typically, only about 12% of the top-scoring compounds actually show activity when tested in biochemical assays. We argue that most scoring functions used for this task have been developed with insufficient thoughtfulness into the datasets on which they are trained and tested, leading to overly simplistic models and/or overtraining. These problems are compounded in the literature because none of the studies reporting new scoring methods have validated their model prospectively within the same study. Here, we report a new strategy for building a training dataset (D-COID) that aims to generate highly-compelling decoy complexes that are individually matched to available active complexes. Using this dataset, we train a general-purpose classifier for virtual screening (vScreenML) that is built on the XGBoost framework of gradient-boosted decision trees. In retrospective benchmarks, our new classifier shows outstanding performance relative to other scoring functions. We additionally evaluate the classifier in a prospective context, by screening for new acetylcholinesterase inhibitors. Remarkably, we find that nearly all compounds selected by vScreenML show detectable activity at 50 {micro}M, with 10 of 23 providing greater than 50% inhibition at this concentration. Without any medicinal chemistry optimization, the most potent hit from this initial screen has an IC50 of 280 nM, corresponding to a Ki value of 173 nM. These results support using the D-COID strategy for training classifiers in other computational biology tasks, and for vScreenML in virtual screening campaigns against other protein targets. Both D-COID and vScreenML are freely distributed to facilitate such efforts.

bioinformatics↗